Axsome Therapeutics price target raised to $180 from $150 at Truist

Truist raised the firm’s price target on Axsome Therapeutics (AXSM) to $180 from $150 and keeps a Buy rating on the shares. The firm’s discussion with 6 doctors who treat ADA – Alzheimer’s disease agitation – indicates that they unanimously viewed AXS-05’s totality of evidence as supportive of approval with front-line use ahead of brexpiprazole, the analyst tells investors in a research note. Truist also cites the comfort with safety profile of Auvelity – AXS-05 – from experiences in MDD – major depressive disorder.